| Literature DB >> 25310007 |
Nicola E Stanczyk1, Eline S Smit2, Daniela N Schulz1, Hein de Vries1, Catherine Bolman3, Jean W M Muris4, Silvia M A A Evers5.
Abstract
BACKGROUND: Although evidence exists for the effectiveness of web-based smoking cessation interventions, information about the cost-effectiveness of these interventions is limited.Entities:
Mesh:
Year: 2014 PMID: 25310007 PMCID: PMC4195710 DOI: 10.1371/journal.pone.0110117
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flowchart of respondents.
Figure 2Intervention design.
Legend: T = time, BL = Baseline, QD = Quit date, 1 m = 1 month, 2 m = 2 months.
Comparability of the video-, text-based and control condition regarding demographics, baseline values of outcomes and health-care-related costs over the last three months (N = 2099).
| Variable | Video (N = 670) | Text (N = 708) | Control (N = 721) |
| X2(df) | P |
| Gender [% female (N)] | 62.2(417) | 60.9(431) | 59.6(430) | .985 (2) | .611 | |
| Age [M (SD)] | 45.54(13.0) | 45.42(12.8) | 46.2(12.5) | 0.770(2, 2096) | .463 | |
| Educational level [% (N)] | 3.978(4) | .409 | ||||
| High | 33.6(225) | 32.6(231) | 34.5(249) | |||
| Medium | 36.9(247) | 36.0(255) | 38.8(280) | |||
| Low | 29.6(198) | 31.4(222) | 26.6(192) | |||
| FTCD score | 5.0(2.3) | 4.9(2.4) | 4.9(2.5) | 0.774(2, 2096) | .461 | |
| Number of cigarettes smoked per day [M (SD)] | 19.0(8.1) | 18.7(8.4) | 19.0(9.2) | 0.286(2, 2096) | .751 | |
| With COPD diseases [% (N)] | 14.5(97) | 14.0(99) | 13.0(94) | 0.630(2) | .730 | |
| With cancer [% (N)] | 1.5(10) | 1.3(9) | 2.1(15) | 1.568(2) | .457 | |
| With diabetes [% (N)] | 4.0(27) | 4.7(33) | 5.4(39) | 1.477(2) | .478 | |
| With cardiovascular diseases [% (N)] | 9.4(63) | 8.5(60) | 12.1(87) | 5.515(2) | .063 | |
| With asthma diseases [% (N)] | 9.4(63) | 8.1(57) | 7.1(51) | 2.532(2) | .282 | |
| Utility score | 0.8(0.2) | 0.8(0.2) | 0.8(0.2) | 0.271(2, 2096) | .762 | |
| Total health-care-related costs (€) | 756.3(1742.9) | 836.4(2509.9) | 793.0(2067.1) | 0.239(2, 2061) | .788 | |
| Prescribed and OTC (€) | 69.3(263.5) | 66.7(262.9) | 78.0(325.7) | 0.301(2, 2062) | .740 | |
| Hospital (€) [M (SD)] | 166.2(812.8) | 252.2(1779.8) | 185.0(1044.6) | 0.863(2, 2096) | .422 | |
| Surgery (€) [M (SD)] | 284.7(1022.1) | 257.7(985.7) | 249.2(968.2) | 0.241(2, 2096) | .786 | |
| Health-care provider (€) [M (SD)] | 230.7(476.3) | 245.4(567.4) | 274.6(867.1) | 0.796(2, 2095) | .451 | |
| Productivity costs (€) [M (SD)] | 718.9(2664.2) | 772.5(2856.5) | 835.0(3165.5) | 0.279(2, 2095) | .757 | |
| Travel costs (€) [M (SD)] | 7.8(15.2) | 7.6(13.8) | 8.3(17.6) | 0.249(2, 2095) | .780 |
Fagerstroem Test for Cigarette Dependence (0 = not addicted, 10 = highly addicted),
based on the Dutch algorithm for the EQ-5D-3L scores,
costs for prior three month,
OTC: over-the-counter.
Mean annual costs a per respondent in the video-, text-based and control condition.
| Cost type | Mean costs (€) (SD) | 95% CI Differences | ||||
| Video | Text | Control | Video-Text | Control-Text | Video- Control | |
|
| 0.22 | 0.22 | 0.22 | |||
|
| 4845(509) | 5279(532) | 4837(464) | −1860.5 to 1018.8 | −1824.6 to 948.6 | −1317.1 to 1424.7 |
| Prescribed and OTC medication (N = 2082) | 310(50) | 422(102) | 286(45) | −359.8 to 91.5 | −372.6 to 60.3 | −107.0 to 159.5 |
| Hospital (N = 2099) | 1026(319) | 895(240) | 697(135) | −582.7 to 1003.2 | −760.0 to 313.7 | −225.9 to1126.0 |
| Surgery (N = 2099) | 127(46) | 172(58) | 143(45) | −197.1 to 95.5 | −180.4 to108.9 | −142.4 to112.9 |
| Health care provider (N = 2086) | 909(95) | 1033(98) | 1041(119) | −389.4 to 143.8 | −293.4 to 313.9 | −431.6 to 158.0 |
|
| 2247(334) | 2372(350) | 2452(389) | −1064.9 to 824.9 | −921.64 to 1114.7 | −1202.1 to 804.8 |
|
| 97(3) | 100(2) | 35(2) | −9.8 to 3.7 | −71.8 to 59.1 | 55.3 to 69.6 |
| Travel costs (N = 2099) | 31(3) | 33(2) | 33(2) | −8.6 to 5.2 | −6.4 to 6.4 | −8.9 to 5.5 |
| Time costs (fixed) | 67(1) | 67(1) | 2(0) | −2.1 to 0.87 |
|
|
Volumes and prices details are available upon request,
based on 5000 bootstrap replications.
Mean annual effect on smoking abstinence and QALY in the video-, text-based and control condition (intention to treat).
| Effects | Video (N = 670) | Text (N = 708) | Control (N = 721) |
| X2(df) | P |
| Prolonged abstinent (N = 2099)[% (N)] | 9.9(66) | 7.3(52) | 6.4(46) | 6.134(2) | .047 | |
| 7-day point prevalence abstinent (N = 2099) [% (N)] | 17.8(119) | 17.7(125) | 16.2(117) | .730(2) | .694 | |
| QALY (EQ-5D-3L) | 0.8(0.2) | 0.8(0.2) | 0.8(0.2) | .017(2, 2085) | .984 |
Based on the Dutch algorithm for EQ-5D-3L scores.
Incremental costs and effects per abstinent smoker and per QALY gained for the video-, text-based and control condition with a willingness-to-pay threshold of €18,000.
| Intervention | |||||
|
|
|
|
|
|
|
| Control | 4,879 | 1.06 | - | - | - |
| Video vs. Control | 4,939 | 1.10 | 60 | 0.04 | 1,500 |
| Text vs. Control | 5,383 | 1.07 | 504 | 0.01 | 50,400 |
| Video vs. Text | 444 | −0.03 | dominated | ||
|
|
|
|
|
|
|
| Control | 4,879 | 0.83 | - | - | - |
| Video vs. Control | 4,939 | 0.83 | 60 | 0.001 | 60,000 |
| Text vs. Control | 5,383 | 0.83 | 504 | −0.002 | dominated |
| Video vs. Text | 444 | −0.003 | dominated |
coded as 2 = prolonged abstinent and 1 not prolonged abstinent,
incremental number of abstinence/QALY,
per abstinent respondent, calculated according to the formula ICER/ICUR = (Ci-Cc)/Ei-Ec),
dominated = less costs, more effects compared to the other condition,
based on the Dutch algorithm for the EQ-5D-3L scores.
Figure 3Primary and sensitivity analyses of cost-effectiveness acceptability curve for the three conditions: video-based, text-based and control condition.
Results from cost-effectiveness and cost-utility analyses based on 1000 bootstrap replications.
| Analysis type | Group (N) | Probability of highest net monetary benefit (WTP = 0),% | Probability of highest net monetary benefit (WTP = 18,000),% | Probability of highest net monetary benefit (WTP = 80,000),% | ||||||||
| Video | Text | Control | Video | Text | Control | Video | Text | Control | Video | Text | Control | |
|
| ||||||||||||
| Prolonged abstinence (PA) | 670 | 708 | 721 | 42 | 16 | 42 | 70 | 11 | 20 | 90 | 7 | 3 |
| QALY (EQ-5D-3L) | 667 | 704 | 717 | 38 | 18 | 45 | 39 | 18 | 43 | 41 | 20 | 39 |
|
| ||||||||||||
| Seven-day point prevalence abstinence (PPA) | 670 | 708 | 721 | 38 | 17 | 46 | 46 | 22 | 31 | 48 | 34 | 18 |
| PA without surgery costs | 670 | 708 | 721 | 41 | 17 | 42 | 68 | 12 | 20 | 90 | 7 | 3 |
| PA without respondent costs | 670 | 708 | 721 | 43 | 20 | 38 | 68 | 14 | 17 | 90 | 7 | 3 |
| PA without medication costs | 670 | 708 | 721 | 36 | 23 | 42 | 61 | 19 | 21 | 87 | 10 | 4 |
| QALY without surgery costs | 667 | 704 | 717 | 43 | 15 | 41 | 44 | 16 | 41 | 44 | 17 | 39 |
| QALY without respondents costs | 667 | 704 | 717 | 41 | 18 | 41 | 43 | 18 | 39 | 45 | 18 | 37 |
| QALY without medication costs | 667 | 704 | 717 | 35 | 27 | 38 | 38 | 26 | 37 | 40 | 24 | 36 |
Coded as 2 = prolonged abstinent and 1 = not prolonged abstinent,
based on the Dutch algorithm for the EQ-5D-3L scores,
coded as 2 = seven-day point prevalence abstinent and 1 = not seven-day point prevalence abstinent;
Figure 4Primary and sensitivity analyses of cost-utility acceptability curve for the three conditions: video-based, text-based and control condition.